Melanotan II (MT2) — Research Protocol

Quickstart Highlights

Melanotan II is a synthetic analog of α-melanocyte-stimulating hormone studied for its ability to increase skin pigmentation and noted for inducing erectile activity as a side effect^[1]. Early human trials identified effective daily doses in the range of 1–2 mg for tanning, with conservative protocols starting lower to minimize side effects such as nausea and flushing^[2][3].

Storage Instructions

Proper storage preserves peptide stability and potency.

• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; keep desiccated to minimize moisture exposure^[7].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks with bacteriostatic water preservative^[7].
• Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if longer storage needed.
• Allow vials to reach room temperature before opening to reduce condensation.

How It Works

Melanotan II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone that binds to melanocortin receptors, particularly MC1R and MC4R^[1]. Activation of MC1R on melanocytes stimulates melanin production and distribution, resulting in increased skin pigmentation even without UV exposure^[2]. Early Phase I studies in humans identified 0.025 mg/kg per day (approximately 1.5–2 mg for an average adult) as an appropriate dose, with measurable tanning observed after just five low doses administered over two weeks^[1]. The peptide’s subcutaneous administration allows for steady melanocortin receptor activation, with effects accumulating over the course of daily injections during the initial tanning phase^[3].

Potential Benefits & Side Effects

Observations from clinical trials and case reports.

Potential Benefits

• Increases skin pigmentation (tanning) without UV exposure requirement^[1][2].
• Tanning effects observable after 5–10 daily injections in most individuals^[1].
• May induce spontaneous erections in men as a noted side effect (MC4R activation)^[3][5].
• Maintenance dosing (1–2× weekly) can sustain pigmentation after initial loading phase^[3].

Common Side Effects

• Nausea (dose-dependent; most common at higher doses)^[1][2].
• Facial flushing and increased skin warmth^[3].
• Reduced appetite and mild fatigue^[1].
• Spontaneous erections or increased libido in men^[5].
• Injection site reactions (redness, mild stinging)^[9].

Serious Risks & Warnings

• Not FDA-approved: Melanotan II is not an approved medication; use carries regulatory and safety risks^[6].
• Dose-limiting toxicity: Severe sympathomimetic symptoms and rhabdomyolysis reported at 6 mg dose^[4].
• Mole changes: May alter pigmentation of existing moles; theoretical melanoma concerns warrant caution^[6].
• Cardiovascular effects: Transient increases in heart rate and blood pressure possible at higher doses^[3].

References

• PubMed — Dorr RT et al. (1996)Phase I clinical study of melanotan-II, evaluation of dosing and safety in healthy volunteers
• International Peptide Society — Melanotan II MonographComprehensive peptide monograph covering dosing protocols and titration guidance
• DermNet NZ — Melanotan II Information for PatientsClinical dermatology guidance on melanotan use, side effects, and maintenance dosing
• PubMed — Nelson ME et al. (2012)Case report: Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
• RxList — Melanotan-II Uses, Side Effects and DosingMedical database overview of melanotan-II pharmacology and clinical effects
• Cell Sciences Inc. — Product Data SheetMelanotan-II storage and stability specifications for lyophilized and reconstituted forms
• MedlinePlus — Subcutaneous InjectionsU.S. National Library of Medicine patient instructions for subcutaneous injection technique
• NCBI Bookshelf — Administration of Parenteral MedicationsComprehensive nursing guide for safe injection practices and sterile technique
• CDC — Vaccine Administration GuidelinesSubcutaneous injection technique, site selection, and best practices from the CDC
• NCBI Bookshelf — Best Practices for Injection SafetyClinical guidelines for aseptic preparation and administration of injectable medications